2025-10-30 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the provided data, formatted for a clear, English presentation.

## RXRX (Recursion Pharmaceuticals Inc.) Analysis

**Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -4.70%
*   **VOO Cumulative Return:** 46.03%
*   **Total Divergence:** -43.5
*   **Relative Divergence:** 14.0 (This means the current divergence is in the 14th percentile of its historical range against VOO).

*Analysis:* RXRX has significantly underperformed the S&P 500 over the analyzed period. The relative divergence indicates that the underperformance is near the lower end of its historical range.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2021-2023  | 22.0%   | 81.0%   | 26.0%   | -0.2  | 4.3    |
| 2022-2024  | 11.0%   | 81.0%   | -10.0%  | 0.1   | 3.0    |
| 2023-2025  | 38.0%   | 80.0%   | -31.0%  | 0.1   | 2.6    |

*Analysis:*
*   **CAGR:** Varies significantly across periods, showing volatility.
*   **MDD:** Consistently high Maximum Drawdown indicates substantial risk.
*   **Alpha:**  Significantly negative Alpha in recent periods suggests underperformance relative to its risk-adjusted expected return.
*   **Beta:** Low Beta indicates low correlation with the market.

**2. Recent Stock Price Movement**

*   **Current Price:** 5.97
*   **Last Market Data:** Price = 5.96, Previous Close = 5.91, Change = 0.85
*   **5-Day Moving Average:** 5.958
*   **20-Day Moving Average:** 5.833
*   **60-Day Moving Average:** 5.2573

*Analysis:* The current price is above both the 5-day and 20-day moving averages, suggesting a short-term upward trend. The price change of 0.85 relative to the previous close suggests a recent positive momentum.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 48.97 (Neutral)
*   **PPO:** -0.3054 (Slightly bearish)
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash" - Suggests a strong buy signal based on the algorithm, aligning with the high MRI.
*   **Recent (20-Day) Relative Divergence Change:** 0.6 (+, indicating short-term increase)
*   **Expected Return:** -26.8% (Long-term, relative to S&P 500)

*Analysis:* The MRI suggests a favorable investment environment, however, the significantly negative Expected Return is a key concern and suggests the model expects RXRX to underperform the S&P 500 significantly over the long term. The recent price change may reflect a short-term reaction, but the long-term outlook is less positive.

**4. Recent News & Significant Events:**

*   **Negative Earnings Preview:** Upcoming Q3 earnings are expected to decline.
*   **Stock Declines:** RXRX stock has declined even while the broader market improves.
*   **Upcoming Earnings Report:** Q3 results to be reported on November 5th.
*   **Valuation Assessment:** Analysis following AI merger news, trial progress, and regulatory updates.
*   **AI Market Growth:** General positive outlook for the AI in Biotechnology market.
*   **Underperformance:** RXRX is dipping more than the broader market.

*Analysis:* Recent news is mixed but leans negative, with concerns about earnings, stock performance, and valuation.

**4-2. Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.62 (Hold)
*   **Target Price:** Average $6.47 (High: $10.00, Low: $3.00)

*Analysis:* Analyst consensus is a "Hold" with a target price slightly above the current price, suggesting modest upside potential but a wide range of opinions.

**5. Recent Earnings Analysis:**

| 날짜        | EPS   | 매출      |
|-------------|-------|-----------|
| 2025-08-05  | -0.41 | 0.02 B$   |
| 2025-05-05  | -0.5  | 0.01 B$   |
| 2024-11-06  | -0.34 | 0.03 B$   |
| 2024-08-08  | -0.4  | 0.01 B$   |
| 2025-08-05  | -0.4  | 0.01 B$   |

*Analysis:* Earnings per share (EPS) are consistently negative, and revenue is relatively low, indicating a lack of profitability.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $0.02B    | -5.54%        |
| 2025-03-31   | $0.01B    | -47.31%       |
| 2024-12-31   | $0.00B    | -183.62%      |
| 2024-09-30   | $0.03B    | 53.69%        |
| 2024-06-30   | $0.01B    | 36.14%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-06-30   | $0.92B    | -18.70%  |
| 2025-03-31   | $0.93B    | -21.68%  |
| 2024-12-31   | $1.03B    | -17.29%  |
| 2024-09-30   | $0.52B    | -18.27%  |
| 2024-06-30   | $0.58B    | -16.69%  |

*Analysis:* Revenue is inconsistent and low. Profit margins are generally negative, with some positive outliers. Return on Equity (ROE) is consistently negative, indicating poor profitability relative to equity. Equity has fluctuated.

**7. 종합 분석 (Overall Analysis)**

RXRX presents a mixed picture:

*   **Negative Performance:** Significant underperformance compared to the S&P 500.
*   **High Risk:** High Maximum Drawdown and volatility.
*   **Unprofitable:** Consistent negative EPS, ROE, and frequently negative profit margins.
*   **Mixed Signals:** Recent price momentum and high MRI contrast with negative expected return and analyst concerns.
*   **External Factors:** Positive outlook for the AI in Biotechnology market could be a long-term tailwind.

**Conclusion:**

RXRX is a high-risk, speculative investment. While the company operates in a potentially high-growth sector (AI in biotechnology), the financials indicate significant challenges. The recent positive price momentum and high MRI should be viewed cautiously in light of the negative earnings, poor profitability, and long-term underperformance expectations. The upcoming earnings report will be critical. The "Hold" rating and target price provide little conviction. Investors should proceed with extreme caution and carefully weigh the risks and potential rewards before considering an investment in RXRX.
